The Stop TB Partnership Working Group on New Drugs’ Annual Meeting has proven valuable as a neutral forum to bring together those working in research and development to get a full understanding of the progress, challenges, and critical issues to developing TB treatment.
The 2021 WGND Annual Meeting took place on Thursday, October 14th at 9AM EDT / 3PM CEST / 6:30PM IST. During the meeting, updates were provided by representatives from pharmaceutical, government agencies, research organizations, non-profits, academia, and others involved in TB research and development. The meeting provided an overview of the current state of the Global TB Drug Pipeline with representatives providing updates on active trials, collaborations, novel compounds, and treatment research.
The meeting was held using Zoom Webinar. A recording of the meeting is available here: https://vimeo.com/640491592
- Working Group on New DrugsWelcome AddressMelvin SpigelmanTB Drug Year-in-ReviewBarbara Laughonhttps://www.newtbdrugs.org/sites/default/files/meetings/files/01_%20Barbara%20Laughon_Year-in-Review.pdfWGND UpdatesZaid Tanvirhttps://www.newtbdrugs.org/sites/default/files/meetings/files/02_Zaid%20Tanvir_WGND%20Update_0.pdf
- TB Drug Development UpdatesERA4TBStewart Colehttps://www.newtbdrugs.org/sites/default/files/meetings/files/03_ERA4TB_Stewart%20Cole.pdfAIDS Clinical Trial GroupGavin Churchyardhttps://www.newtbdrugs.org/sites/default/files/meetings/files/04_ACTG_Gavin%20Churchyard.pdfTB AllianceUlrike BuchwaldMorounfolu Olugbosihttps://www.newtbdrugs.org/sites/default/files/meetings/files/05_TB%20Alliance_Ulrike%20Buchwald_Folu%20Olugbosi.pdfJanssenAlexander Pymhttps://www.newtbdrugs.org/sites/default/files/meetings/files/06_Janssen_Alex%20Pym_to_post.pdfGlaxoSmithKlineRobert Bateshttps://www.newtbdrugs.org/sites/default/files/meetings/files/07_GSK_Rob%20Bates.pdfBEAT TuberculosisFrancesca Conradiehttps://www.newtbdrugs.org/sites/default/files/meetings/files/08_BEAT%20TB_Francesca%20Conradie.pdfTB-PRACTECALIlaria Mottahttps://www.newtbdrugs.org/sites/default/files/meetings/files/09_TB-PRACTECAL_Ilaria%20Motta.pdfTRUNCATE-TBNicholas Patonhttps://www.newtbdrugs.org/sites/default/files/meetings/files/10_TRUNCATE%20TB_Nick%20Paton.pdfUS Centers for Disease Control / TB Trials ConsortiumKatya Kurbatovahttps://www.newtbdrugs.org/sites/default/files/meetings/files/11_TBTC_Katya%20Kurbatova.rev_.pdfOtsuka PharmaceuticalsJeffrey Hafkinhttps://www.newtbdrugs.org/sites/default/files/meetings/files/12_Otsuka_Jeffrey%20Hafkin.pdfGates Medical Research InstituteCharles Wellshttps://www.newtbdrugs.org/sites/default/files/meetings/files/13_GMRI_Charles%20Wells.pdfPanACEA, Unite4TB, & LM University of MunichMartin BoereeNorbert HeinrichMichael Hoelscherhttps://www.newtbdrugs.org/sites/default/files/meetings/files/14_PanACEA_Unite4TB_LMU_Martin%20Boeree_Michael%20Hoelscher_Norbert%20Heinrich.pdfendTBCarole Mitnickhttps://www.newtbdrugs.org/sites/default/files/meetings/files/15_endTB_Carole%20Mitnick_2021.pdf